Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird

Baird analyst Brian Skorney lowered the firm’s price target on Eiger BioPharmaceuticals to $3 from $29 and keeps an Outperform rating on the shares. The analyst said although the experimental arms in it D-LIVR trial technically met statistical signficance on the primary endpoint, the results fell well short of what he see as viable for commercialization.